This observation may be hinted by the results of the phase 3 KEYNOTE-789 trial (NCT03515837), which evaluates the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin), with or without pembrolizumab, in the treatment of adults with EGFR-TKI-resistant, EGFR-mutated, metastatic nonsquamous NSCLC tumors, including first-line osimertinib failure. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.